Early Use of Remdesivir in Patients Hospitalized With COVID-19 Improves Clinical Outcomes: A Retrospective Observational Study.
COVID-19
SARS-CoV-2
clinical outcomes
length of stay
remdesivir
Journal
Infectious diseases in clinical practice (Baltimore, Md.)
ISSN: 1056-9103
Titre abrégé: Infect Dis Clin Pract (Baltim Md)
Pays: United States
ID NLM: 9204234
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
entrez:
20
9
2021
pubmed:
21
9
2021
medline:
21
9
2021
Statut:
ppublish
Résumé
Remdesivir treatment, like most antiviral drugs, is likely to be most effective when used early in the course of coronavirus disease 2019 (COVID-19). Optimal timing of remdesivir for the treatment of COVID-19 remains unclear. The aim of this study was to determine whether early treatment with remdesivir improves clinical outcomes: length of stay, need for mechanical ventilation, and death. We conducted a retrospective observational study of patients hospitalized with COVID-19 who received remdesivir therapy within 10 days of symptom onset at a large health system in Georgia, United States. We identified a total of 475 patients. Initiation of therapy 3 days or less from first positive SARS-CoV-2 improved length of stay (15.7 days) compared with those started on therapy more than 3 days after a positive test (19.3 days) ( Our data show that early treatment with remdesivir in patients hospitalized with COVID-19 shortened length of stay.
Sections du résumé
BACKGROUND
BACKGROUND
Remdesivir treatment, like most antiviral drugs, is likely to be most effective when used early in the course of coronavirus disease 2019 (COVID-19). Optimal timing of remdesivir for the treatment of COVID-19 remains unclear.
OBJECTIVES
OBJECTIVE
The aim of this study was to determine whether early treatment with remdesivir improves clinical outcomes: length of stay, need for mechanical ventilation, and death.
METHODS
METHODS
We conducted a retrospective observational study of patients hospitalized with COVID-19 who received remdesivir therapy within 10 days of symptom onset at a large health system in Georgia, United States.
RESULTS
RESULTS
We identified a total of 475 patients. Initiation of therapy 3 days or less from first positive SARS-CoV-2 improved length of stay (15.7 days) compared with those started on therapy more than 3 days after a positive test (19.3 days) (
CONCLUSIONS
CONCLUSIONS
Our data show that early treatment with remdesivir in patients hospitalized with COVID-19 shortened length of stay.
Identifiants
pubmed: 34539162
doi: 10.1097/IPC.0000000000001023
pii: IDCP_210039
pmc: PMC8436815
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e282-e286Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no funding or conflicts of interest to disclose.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
N Engl J Med. 2020 Nov 5;383(19):1827-1837
pubmed: 32459919
Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34
pubmed: 30930717
Vaccines (Basel). 2020 May 14;8(2):
pubmed: 32423059
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440